Coya Therapeutics, Inc.
COYAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCoya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). The company carries a $92.4M market cap, placing it firmly in the micro-cap category. Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Market Cap
$92.4M
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
-2.05
EPS (TTM)
$-1.07
EPS (Fwd)
$-1.92
ROE
-60.5%
ROA
-32.3%
Cash
$43.2M
Total Debt
$0
Free CF
-$10.9M
52W Change
-39.1%
Annual Financials
Cash vs Debt
Where COYA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, COYA finished 9.87% below its 150-day moving average ($4.66) and 10.45% below its 200-day moving average ($4.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COYA overbought or oversold?
At the October 20, 2026 close, COYA's RSI(14) was 25.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Coya Therapeutics, Inc. reports $43.2M in cash and $0 in total debt. Free cash flow is running at -$10.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -60.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Coya Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Coya Therapeutics, Inc. and its sector.